BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang S, K R J, Lim S, Choi TG, Kim JH, Akter S, Jang M, Ahn HJ, Kim HY, Windisch MP, Khadka DB, Zhao C, Jin Y, Kang I, Ha J, Oh BC, Kim M, Kim SS, Cho WJ. Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections. J Med Chem 2015;58:9546-61. [PMID: 26613291 DOI: 10.1021/acs.jmedchem.5b01064] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Murlykina MV, Kolomiets OV, Kornet MM, Sakhno YI, Desenko SM, Dyakonenko VV, Shishkina SV, Brazhko OA, Musatov VI, Tsygankov AV, Van der Eycken EV, Chebanov VA. Doebner-type pyrazolopyridine carboxylic acids in an Ugi four-component reaction. Beilstein J Org Chem 2019;15:1281-8. [PMID: 31293676 DOI: 10.3762/bjoc.15.126] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Ganesan A, Barakat K. Applications of computer-aided approaches in the development of hepatitis C antiviral agents. Expert Opin Drug Discov 2017;12:407-25. [PMID: 28164720 DOI: 10.1080/17460441.2017.1291628] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
3 Vidotto A, Morais AT, Ribeiro MR, Pacca CC, Terzian AC, Gil LH, Mohana-Borges R, Gallay P, Nogueira ML. Systems Biology Reveals NS4B-Cyclophilin A Interaction: A New Target to Inhibit YFV Replication. J Proteome Res 2017;16:1542-55. [PMID: 28317380 DOI: 10.1021/acs.jproteome.6b00933] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
4 Han J, Kyu Lee M, Jang Y, Cho WJ, Kim M. Repurposing of cyclophilin A inhibitors as broad-spectrum antiviral agents. Drug Discov Today 2022:S1359-6446(22)00207-0. [PMID: 35609743 DOI: 10.1016/j.drudis.2022.05.016] [Reference Citation Analysis]
5 Han J, Lee HW, Jin Y, Khadka DB, Yang S, Li X, Kim M, Cho WJ. Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment. Eur J Med Chem 2020;188:112031. [PMID: 31923861 DOI: 10.1016/j.ejmech.2019.112031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Liu CW, Atkinson MA, Zhang Q. Type 1 diabetes cadaveric human pancreata exhibit a unique exocrine tissue proteomic profile. Proteomics 2016;16:1432-46. [PMID: 26935967 DOI: 10.1002/pmic.201500333] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
7 Ahmed-Belkacem A, Colliandre L, Ahnou N, Nevers Q, Gelin M, Bessin Y, Brillet R, Cala O, Douguet D, Bourguet W, Krimm I, Pawlotsky JM, Guichou JF. Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities. Nat Commun 2016;7:12777. [PMID: 27652979 DOI: 10.1038/ncomms12777] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
8 Li G, De Clercq E. Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Res. 2017;142:83-122. [PMID: 28238877 DOI: 10.1016/j.antiviral.2017.02.014] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 18.6] [Reference Citation Analysis]
9 Li X, Han J, Lee HW, Yoon YS, Jin Y, Khadka DB, Yang S, Kim M, Cho WJ. SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection. Bioorg Med Chem 2020;28:115679. [PMID: 32912430 DOI: 10.1016/j.bmc.2020.115679] [Reference Citation Analysis]
10 Jin G, Lee J, Lee K. Chemical genetics-based development of small molecules targeting hepatitis C virus. Arch Pharm Res 2017;40:1021-36. [PMID: 28856597 DOI: 10.1007/s12272-017-0949-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]